as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 26 Oct 2026
₹410.6
Change
+32.95 (8.73%)
Open
₹384.0
Prev. Close
₹377.65
Day High
₹446.6
Day Low
₹381.45
Volume Analysis
Traded
3,752,978
Delivered
7,605,200
Delivery %
43.67%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year revenue growth (20.6%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹509.46 | ₹478.03 | ₹444.31 | ₹412.88 | ₹379.16 | ₹347.73 | ₹314.01 |
| Fibonacci | ₹478.03 | ₹453.14 | ₹437.77 | ₹412.88 | ₹387.99 | ₹372.62 | ₹347.73 |
| Camarilla | ₹428.52 | ₹422.54 | ₹416.57 | ₹412.88 | ₹404.63 | ₹398.66 | ₹392.68 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
—
1 Month
—
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
9.91%
Net margin 5.7% × asset turnover 0.95x × equity multiplier 1.83x
Company Overview
Market Cap
₹3,647 Cr
P/E (TTM)
55.6
ROE
10.4%
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 23 Oct 2026. Not investment advice.
TopFund Analysis
Sahajanand Medical Tech L lands in the middle of the pack on TopFund's composite fundamentals check, at 54/100. The strongest factor is Growth (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Strong 3-year revenue growth (20.6%).
TopFund Score — Fundamentals Quality
54/100 — AverageData confidence: 65/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 26 Oct 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Business Quality
Liquidity
From Screener.in
- −Company has a low return on equity of 4.42% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2026 | |
|---|---|
| Sales + | 352 |
| Expenses + | 303 |
| Operating Profit | 49 |
| OPM % | 14.0% |
| Other Income + | 3 |
| Interest | 7 |
| Depreciation | 20 |
| Profit before tax | 24 |
| Tax % | 38.0% |
| Net Profit + | 15 |
| EPS in Rs | 1 |
| Raw PDF | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 589 | 690 | 902 | 1,025 | 1,210 |
| Expenses + | 539 | 641 | 792 | 896 | 1,039 |
| Operating Profit | 49 | 48 | 110 | 129 | 171 |
| OPM % | 8.0% | 7.0% | 12.0% | 13.0% | 14.0% |
| Other Income + | -39 | -19 | 7 | -5 | 8 |
| Interest | 20 | 22 | 19 | 21 | 24 |
| Depreciation | 35 | 38 | 64 | 63 | 74 |
| Profit before tax | -45 | -30 | 33 | 41 | 80 |
| Tax % | 60.0% | 61.0% | 122.0% | 38.0% | 14.0% |
| Net Profit + | -72 | -49 | -7 | 25 | 69 |
| EPS in Rs | -8 | -5 | -1 | 2 | 6 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Reserves | 325 | 392 | 530 | 556 | 686 |
| Borrowings + | 325 | 386 | 201 | 254 | 306 |
| Other Liabilities + | 191 | 212 | 227 | 274 | 273 |
| Total Liabilities | 849 | 999 | 968 | 1,093 | 1,274 |
| Fixed Assets + | 203 | 207 | 296 | 288 | 343 |
| CWIP | 60 | 122 | 13 | 6 | 9 |
| Investments | 0 | 0 | 6 | 5 | 59 |
| Other Assets + | 586 | 669 | 652 | 794 | 863 |
| Total Assets | 849 | 999 | 968 | 1,093 | 1,274 |
| Equity Capital | 9 | 9 | 10 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 46 | 17 | 41 | 74 | 105 |
| Cash from Investing Activity + | -169 | -154 | -42 | -50 | -120 |
| Cash from Financing Activity + | 212 | 109 | 13 | 6 | -12 |
| Net Cash Flow | 89 | -29 | 12 | 29 | -26 |
| Free Cash Flow | 18 | -76 | 2 | 26 | 17 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 116 | 86 | 55 | 85 | 79 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Which Mutual Funds Hold Sahajanand Medical Tech L?
Frequently Asked Questions about Sahajanand Medical Tech L
Sahajanand Medical Tech L (SMT) closed at ₹410.6 on NSE on 26 October 2026, up 32.95 (8.73%) from the previous close.
Sahajanand Medical Tech L trades on the NSE (National Stock Exchange of India) under the symbol SMT.
Sahajanand Medical Tech L has a trailing twelve-month P/E (price-to-earnings) ratio of 55.6.
Sahajanand Medical Tech L has a market capitalisation of ₹3,647 crore.
Sahajanand Medical Tech L has a TopFund Quality Score of 54/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sahajanand Medical Tech L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.